The HFE Knockout SK-HEP-1 Polyclonal Cells product is a CRISPR/Cas9-edited human cell population designed for targeted disruption of the HFE gene within the SK-HEP-1 hepatic adenocarcinoma background. This polyclonal knockout population provides a genetically heterogeneous loss-of-function model, avoiding single-cell clone biases and enabling robust investigation of HFE-dependent signaling and iron homeostasis. The cells are delivered as a ready-to-use format, validated for the absence of wild-type HFE protein expression, and suitable for a broad range of downstream functional assays in hepatocellular research contexts.
The SK-HEP-1 host cell line was originally derived from the ascitic fluid of a male patient diagnosed with hepatic adenocarcinoma. Despite its epithelial tumor origin, SK-HEP-1 exhibits notable endothelial characteristics, including expression of certain endothelial markers, making it a unique platform for studying cross-talk between hepatic and vascular biology. Its adherent growth and stable karyotype facilitate reproducible experimental workflows in cancer cell biology and metabolic disease research.
HFE encodes a major histocompatibility complex class I-like protein that acts as a critical regulator of systemic iron status. It forms complexes with transferrin receptors TFR1 and TFR2 and beta-2-microglobulin (B2M) at the cell surface, and interacts with the co-receptor hemojuvelin (HJV) to potentiate BMP-SMAD signaling. This pathway, activated by the ligand BMP6, involves receptor-mediated phosphorylation of SMAD1/5/8, which together with SMAD4 transcriptionally upregulates hepcidin (HAMP) expression. The upstream regulators IL-6 and iron regulatory proteins further modulate this network. Consequently, HFE disruption leads to diminished hepcidin production, causing unregulated iron export via the ferroportin channel SLC40A1 and cellular iron accumulation.
In the SK-HEP-1 hepatocellular context, HFE knockout disrupts the iron-sensing machinery that governs hepcidin transcription, recreating a disease-relevant phenotype of dysregulated iron metabolism. This model captures molecular defects seen in hereditary hemochromatosis, including impaired BMP-SMAD signal transduction and aberrant TFR1 expression dynamics. The endothelial-like properties of SK-HEP-1 also permit exploration of HFE’s role in non-parenchymal liver cells, extending the model’s utility to vascular iron handling and its interplay with hepatic iron storage.
This polyclonal knockout cell population is ideally suited for mechanistic studies of iron regulation, hereditary hemochromatosis research, and preclinical screening of iron chelators. Typical experimental readouts include Western blotting to assess HFE pathway components, RT-qPCR for HAMP mRNA quantification, iron content measurement via biochemical assays, hepcidin ELISA, and TFR1 binding analyses. Researchers can employ these cells to dissect the BMP-SMAD-hepcidin axis, test small-molecule modulators, or coculture with other hepatic cell types to model liver iron overload. For additional product information and technical support, please contact Ascent Research.
